• myGriffith
    • Staff portal
    • Contact Us⌄
      • Future student enquiries 1800 677 728
      • Current student enquiries 1800 154 055
      • International enquiries +61 7 3735 6425
      • General enquiries 07 3735 7111
      • Online enquiries
      • Staff phonebook
    View Item 
    •   Home
    • Griffith Research Online
    • Journal articles
    • View Item
    • Home
    • Griffith Research Online
    • Journal articles
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

  • All of Griffith Research Online
    • Communities & Collections
    • Authors
    • By Issue Date
    • Titles
  • This Collection
    • Authors
    • By Issue Date
    • Titles
  • Statistics

  • Most Popular Items
  • Statistics by Country
  • Most Popular Authors
  • Support

  • Contact us
  • FAQs
  • Admin login

  • Login
  • How can we improve the use of established therapies in PsA? (Editorial)

    Author(s)
    Nash, P
    Griffith University Author(s)
    Nash, Peter
    Year published
    2020
    Metadata
    Show full item record
    Abstract
    Just because nobody complains it doesn’t mean all parachutes are perfect. — Benny Hill While there has been an expansion in therapeutic targets and a renaissance of novel therapies in psoriatic arthritis (PsA)1, the efficacy and safety of tumor necrosis factor inhibitors (TNFi) in PsA have long been established2,3. With an influx of “cheaper” biosimilars attractive to regulators and reimbursers, it behooves rheumatologists spoiled with choice to maximize efficient use of readily accessible agents. Immunogenicity due to anti-drug antibodies (ADAb) in TNFi therapy has been shown to affect drug levels and subsequently to affect ...
    View more >
    Just because nobody complains it doesn’t mean all parachutes are perfect. — Benny Hill While there has been an expansion in therapeutic targets and a renaissance of novel therapies in psoriatic arthritis (PsA)1, the efficacy and safety of tumor necrosis factor inhibitors (TNFi) in PsA have long been established2,3. With an influx of “cheaper” biosimilars attractive to regulators and reimbursers, it behooves rheumatologists spoiled with choice to maximize efficient use of readily accessible agents. Immunogenicity due to anti-drug antibodies (ADAb) in TNFi therapy has been shown to affect drug levels and subsequently to affect clinical response in rheumatoid arthritis (RA)4 and inflammatory bowel disease5. In turn it affects safety, inducing infusion and injection site reactions (ISR), but the issue has been less well studied in patients with PsA.
    View less >
    Journal Title
    Journal of Rheumatology
    Volume
    47
    Issue
    8
    DOI
    https://doi.org/10.3899/jrheum.190999
    Subject
    Clinical Sciences
    Immunology
    Public Health and Health Services
    Publication URI
    http://hdl.handle.net/10072/397654
    Collection
    • Journal articles

    Footer

    Disclaimer

    • Privacy policy
    • Copyright matters
    • CRICOS Provider - 00233E

    Tagline

    • Gold Coast
    • Logan
    • Brisbane - Queensland, Australia
    First Peoples of Australia
    • Aboriginal
    • Torres Strait Islander